Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13972055 | 1.00 | PNMT (0.57) | PNMTHTR2AHTR2CHTR2BTAAR1 | |
| SCHEMBL7562470 | 0.82 | GABRA1 (0.50) | HTR2AHTR2BSLC6A2SLC6A3 | |
| SCHEMBL892653 | 0.82 | TAAR1 (0.57) | PNMTHTR2AHTR2CHTR2BTAAR1 | |
| SCHEMBL14071835 | 0.82 | PNMT (0.52) | PNMTHTR2AHTR2CHTR2BTAAR1 | |
| SCHEMBL13248703 | 0.82 | SLC6A2 (0.52) | PNMTHTR2AHTR2CHTR2BTAAR1 | |
| SCHEMBL20079631 | 0.80 | PNMT (0.50) | PNMTHTR2AHTR2CHTR2BTAAR1 | |
| Hydrochloric Acid SCHEMBL11091077 | 0.80 | TAAR1 (0.55) | PNMTHTR2AHTR2CHTR2BTAAR1 | |
| Hydrochloric Acid SCHEMBL3118224 | 0.80 | PNMT (0.50) | PNMTHTR2AHTR2CHTR2BTAAR1 | |
| Hydrochloric Acid SCHEMBL3108070 | 0.80 | SLC6A2 (0.50) | PNMTHTR2AHTR2CHTR2BTAAR1 | |
| SCHEMBL28523195 | 0.79 | SLC6A4 (0.38) | PNMTHTR2AHTR2CHTR2BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112213412-A | Method for detecting drug and metabolite thereof in hair | 四川警察学院 | 2021-01-12 | — | — | CN | claimed |
| US-20200060997-A1 | TARR Receptor Agonists for Sexual Dysfunction | JOHN MCCOY | 2020-02-27 | — | — | US | claimed |
| EP-3366306-A2 | USE OF SOME PEPTIDES IN DIAGNOSIS AND TREATMENT OF DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-08-29 | — | — | EP | claimed |
| EP-3351262-A1 | CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-07-25 | — | — | EP | claimed |
| US-20160000815-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2016-01-07 | — | — | US | claimed |
| CN-103615927-B | Blower motor external valve water-cooling system cooling tower | STATE GRID CORPORATION OF CHINA (CN) | 2015-08-19 | — | — | CN | claimed |
| CN-103633740-B | Telecontrol channel fault monitoring device | STATE GRID CORPORATION OF CHINA (CN) | 2015-08-19 | — | — | CN | claimed |
| CN-103434300-B | Anti-fake bill allowing codes to be changeable | ZHENGZHOU TUNGKONG SECURITY PRINTING CO LTD | 2015-04-15 | — | — | CN | claimed |
| US-20140142140-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2014-05-22 | — | — | US | claimed |
| EP-2729216-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2014-05-14 | — | — | EP | claimed |
| WO-2013007698-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2013-01-17 | — | — | WO | claimed |
| JP-2011529923-A | — | — | 2011-12-15 | — | — | JP | claimed |
| CN-102170874-A | Compositions and methods for treating psychiatric disorders | GOSFORTH CT HOLDINGS PTY LTD | 2011-08-31 | — | — | CN | claimed |
| US-20110207718-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2011-08-25 | — | — | US | claimed |
| EP-2331088-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2011-06-15 | — | — | EP | claimed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010015029-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2010-02-11 | — | — | WO | claimed |
| WO-2026106796-A1 | SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS | FOLLEA INTERNATIONAL (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2008095253-A1 | TREATMENT OF ADHD | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2008-08-14 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | PNMT 1/4885HTR2A 18/4885HTR2C 44/4885 |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | MC1R, TYR, MITF | PNMT 56/4885HTR2A 62/4885HTR2C 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.